NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
Clinical Trials
5 trialsNCT01686334 2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2 Active not recruiting
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT01843179 2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2 Withdrawn